Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus

Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus [50 patients (30 males, 20 females); mean±SD age: 58.7±9.2 years, body mass index: 28.2±4.1'kg/m2], in whom glucose control could not be achieved despite treatment with metformin, sulphonylurea, and/or insulin. The patients were given 4'mg/day rosiglitazone for 3 months in addition to their usual treatment. Serum paraoxonase activity, malondialdehyde, homocysteine, and lipid profile were measured at the time of initiation and at the end of therapy with rosiglitazone. After rosiglitazone therapy, serum levels of HDL-C, apolipoprotein A-1, and paraoxonase activity increased significantly (P<0.05) and malondialdehyde, homocysteine, lipoprotein(a), and glucose levels decreased significantly (P<0.05), but no significant changes in levels of total cholesterol and apolipoprotein B were observed. Triglyceride levels also increased significantly (P<0.05). Rosiglitazone treatment led to an improvement in glycemic control and to an increase in paraoxonase activity and HDL-C levels. Although rosiglitazone showed favorable effects on oxidant/antioxidant balance and lipid profile, further studies are needed to determine the effect of rosiglitazone on cardiovascular risk factors and cardiovascular morbidity and mortality.

Saved in:
Bibliographic Details
Main Authors: Atamer,Y., Atamer,A., Can,A.S., Hekimoğlu,A., Ilhan,N., Yenice,N., Koçyiğit,Y.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2013
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000600528
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2013000600528
record_format ojs
spelling oai:scielo:S0100-879X20130006005282015-10-08Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitusAtamer,Y.Atamer,A.Can,A.S.Hekimoğlu,A.Ilhan,N.Yenice,N.Koçyiğit,Y. Rosiglitazone Diabetes mellitus type 2 Paraoxonase Lipoproteins Homocysteine Lipid peroxidation Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus [50 patients (30 males, 20 females); mean±SD age: 58.7±9.2 years, body mass index: 28.2±4.1'kg/m2], in whom glucose control could not be achieved despite treatment with metformin, sulphonylurea, and/or insulin. The patients were given 4'mg/day rosiglitazone for 3 months in addition to their usual treatment. Serum paraoxonase activity, malondialdehyde, homocysteine, and lipid profile were measured at the time of initiation and at the end of therapy with rosiglitazone. After rosiglitazone therapy, serum levels of HDL-C, apolipoprotein A-1, and paraoxonase activity increased significantly (P<0.05) and malondialdehyde, homocysteine, lipoprotein(a), and glucose levels decreased significantly (P<0.05), but no significant changes in levels of total cholesterol and apolipoprotein B were observed. Triglyceride levels also increased significantly (P<0.05). Rosiglitazone treatment led to an improvement in glycemic control and to an increase in paraoxonase activity and HDL-C levels. Although rosiglitazone showed favorable effects on oxidant/antioxidant balance and lipid profile, further studies are needed to determine the effect of rosiglitazone on cardiovascular risk factors and cardiovascular morbidity and mortality.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.46 n.6 20132013-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000600528en10.1590/1414-431X20132818
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Atamer,Y.
Atamer,A.
Can,A.S.
Hekimoğlu,A.
Ilhan,N.
Yenice,N.
Koçyiğit,Y.
spellingShingle Atamer,Y.
Atamer,A.
Can,A.S.
Hekimoğlu,A.
Ilhan,N.
Yenice,N.
Koçyiğit,Y.
Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
author_facet Atamer,Y.
Atamer,A.
Can,A.S.
Hekimoğlu,A.
Ilhan,N.
Yenice,N.
Koçyiğit,Y.
author_sort Atamer,Y.
title Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
title_short Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
title_full Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
title_fullStr Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
title_full_unstemmed Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
title_sort effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
description Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus [50 patients (30 males, 20 females); mean±SD age: 58.7±9.2 years, body mass index: 28.2±4.1'kg/m2], in whom glucose control could not be achieved despite treatment with metformin, sulphonylurea, and/or insulin. The patients were given 4'mg/day rosiglitazone for 3 months in addition to their usual treatment. Serum paraoxonase activity, malondialdehyde, homocysteine, and lipid profile were measured at the time of initiation and at the end of therapy with rosiglitazone. After rosiglitazone therapy, serum levels of HDL-C, apolipoprotein A-1, and paraoxonase activity increased significantly (P<0.05) and malondialdehyde, homocysteine, lipoprotein(a), and glucose levels decreased significantly (P<0.05), but no significant changes in levels of total cholesterol and apolipoprotein B were observed. Triglyceride levels also increased significantly (P<0.05). Rosiglitazone treatment led to an improvement in glycemic control and to an increase in paraoxonase activity and HDL-C levels. Although rosiglitazone showed favorable effects on oxidant/antioxidant balance and lipid profile, further studies are needed to determine the effect of rosiglitazone on cardiovascular risk factors and cardiovascular morbidity and mortality.
publisher Associação Brasileira de Divulgação Científica
publishDate 2013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000600528
work_keys_str_mv AT atamery effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus
AT atamera effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus
AT canas effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus
AT hekimoglua effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus
AT ilhann effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus
AT yenicen effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus
AT kocyigity effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus
_version_ 1756391425249902592